TY - JOUR
T1 - Monoclonal antibodies as disease modifying therapy in multiple sclerosis
AU - Longbrake, Erin E.
AU - Parks, Becky J.
AU - Cross, Anne H.
N1 - Funding Information:
Acknowledgments Erin E. Longbrake is supported by a Sylvia Lawry Fellowship from the National Multiple Sclerosis Society. Becky J. Parks has received grant support from the National MS Society, National Institutes of Health, and US Department of Defense. Anne H. Cross was supported in part by the Manny and Rosalyn Rosenthal-Dr. John Trotter Chair in Neuroimmunology of the Barnes-Jewish Hospital Foundation.
PY - 2013/11
Y1 - 2013/11
N2 - Multiple sclerosis (MS), a demyelinating disease of the central nervous system, was untreatable until the mid- 1990s when beta-interferons and glatiramer acetate were introduced. These agents, while effective, were relatively nonspecific in action. Over the last 10 years, research has focused toward developing more targeted therapies for the disease. Monoclonal antibodies (mAbs) have been central to these efforts and many of the mAbs studied in MS have been singularly effective. We review here the 6 monoclonal antibodies that have been approved for MS or are in late-stage clinical trials, focusing on the drugs' efficacy and safety. Additionally, we review several monoclonal antibodies that were studied in MS but were found to be ineffective or even deleterious in this patient population.
AB - Multiple sclerosis (MS), a demyelinating disease of the central nervous system, was untreatable until the mid- 1990s when beta-interferons and glatiramer acetate were introduced. These agents, while effective, were relatively nonspecific in action. Over the last 10 years, research has focused toward developing more targeted therapies for the disease. Monoclonal antibodies (mAbs) have been central to these efforts and many of the mAbs studied in MS have been singularly effective. We review here the 6 monoclonal antibodies that have been approved for MS or are in late-stage clinical trials, focusing on the drugs' efficacy and safety. Additionally, we review several monoclonal antibodies that were studied in MS but were found to be ineffective or even deleterious in this patient population.
KW - Clinical trials
KW - Diseasemodifying therapy
KW - Monoclonal antibodies
KW - Multiple sclerosis
UR - http://www.scopus.com/inward/record.url?scp=84883646573&partnerID=8YFLogxK
U2 - 10.1007/s11910-013-0390-z
DO - 10.1007/s11910-013-0390-z
M3 - Article
C2 - 24027005
AN - SCOPUS:84883646573
SN - 1528-4042
VL - 13
JO - Current neurology and neuroscience reports
JF - Current neurology and neuroscience reports
IS - 11
M1 - 390
ER -